LAVA Therapeutics Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
LAVA Therapeutics dropped an 8-K on 3/28 detailing financials. Check it out.
AI Summary
LAVA Therapeutics N.V. filed an 8-K on March 28, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in The Netherlands and its principal executive offices are located in Utrecht.
Why It Matters
This 8-K filing provides crucial updates on LAVA Therapeutics' financial performance and condition, which is essential for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- March 28, 2025 (date) — Date of earliest event reported
- The Netherlands (location) — State of incorporation
- Utrecht (location) — Address of principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on March 28, 2025.
Where is LAVA Therapeutics N.V. incorporated?
LAVA Therapeutics N.V. is incorporated in The Netherlands.
What is the address of LAVA Therapeutics N.V.'s principal executive offices?
The principal executive offices are located at Yalelaan 62, Utrecht, The Netherlands.
Does this filing mention any former company names?
Yes, the filing notes a former company name of 'LAVA Therapeutics BV' with a date of name change of January 15, 2021.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding LAVA Therapeutics NV.